Top

Current Dermatology Reports

Published in:

01-03-2018 | Psoriasis (Jaishin Wu, Section Editor)

Update on Oral Therapy for Psoriasis

Authors: Fernando Valenzuela, Javier Fernández, Pablo Santa María

Published in: Current Dermatology Reports | Issue 1/2018

Abstract

Purpose of Review

The aim of this review article is to summarize the information of oral treatments of psoriasis, with emphasis in new information and newer drugs.

Recent Findings

Methotrexate has an adequate efficacy and safety profile with low cost and large real-life evidence. Cyclosporine’s therapeutic power is abated by the long-term safety issues. Acitretin has a niche in special circumstances such as combination with phototherapy, HIV population, or special forms of psoriasis such as palmoplantar, pustular, and erythrodermic psoriasis. Apremilast, the newer available drug of this group demonstrates a modest but acceptable efficacy and good safety in this population. Other drugs have been evaluated with different results in this field.

Summary

Oral therapy for psoriasis is widely used in patients with moderate to severe disease; thus, it is crucial to know the latest information and indications as well as the recent development of new drugs.

Aslam A, Griffiths CE. Drug therapies in dermatology. Clin Med (London, England). 2014;14(1):47–53. https://doi.org/10.7861/clinmedicine.14-1-47.CrossRef

Torres T, Filipe P. Small molecules in the treatment of psoriasis. Drug Dev Res. 2015;76(5):215–27. https://doi.org/10.1002/ddr.21263.CrossRefPubMed

Gooderham M. Small molecules: an overview of emerging therapeutic options in the treatment of psoriasis. Skin Ther Lett. 2013;18(7):1–4.

Palfreeman AC, McNamee KE, McCann FE. New developments in the management of psoriasis and psoriatic arthritis: a focus on apremilast. Drug Design Dev Ther. 2013;7:201–10.CrossRef

•• Nast A, Gisondi P, Ormerod AD, Saiag P, Smith C, Spuls PI, et al. European S3-Guidelines on the systemic treatment of psoriasis vulgaris—update 2015—short version—EDF in cooperation with EADV and IPC. J Eur Acad Dermatol Venereol: JEADV. 2015;29(12):2277–94. A recent evidence-based guidelines mandatory to psoriasis involved physicians. https://doi.org/10.1111/jdv.13354.CrossRefPubMed

Menting SP, Dekker PM, Limpens J, Hooft L, Spuls PI. Methotrexate dosing regimen for plaque-type psoriasis: a systematic review of the use of test-dose, start-dose, dosing scheme, dose adjustments, maximum dose and folic acid supplementation. Acta Derm Venereol. 2016;96(1):23–8. https://doi.org/10.2340/00015555-2081.CrossRefPubMed

•• West J, Ogston S, Foerster J. Safety and efficacy of methotrexate in psoriasis: a meta-analysis of published trials. PloS one. 2016;11(5):e0153740. Important information regarding methotrexate previous evidence. https://doi.org/10.1371/journal.pone.0153740.CrossRefPubMedPubMedCentral

Nast A, Kopp I, Augustin M, Banditt KB, Boehncke WH, Follmann M, et al. German evidence-based guidelines for the treatment of psoriasis vulgaris (short version). Arch Dermatol Res. 2007;299(3):111–38. https://doi.org/10.1007/s00403-007-0744-y.CrossRefPubMedPubMedCentral

Mahrle G, Schulze HJ, Farber L, Weidinger G, Steigleder GK. Low-dose short-term cyclosporine versus etretinate in psoriasis: improvement of skin, nail, and joint involvement. J Am Acad Dermatol. 1995;32(1):78–88. https://doi.org/10.1016/0190-9622(95)90189-2.CrossRefPubMed

10.

Heydendael VM, Spuls PI, Opmeer BC, de Borgie CA, Reitsma JB, Goldschmidt WF, et al. Methotrexate versus cyclosporine in moderate-to-severe chronic plaque psoriasis. N Engl J Med. 2003;349(7):658–65. https://doi.org/10.1056/NEJMoa021359.CrossRefPubMed

11.

Flytström I, Stenberg B, Svensson A, Bergbrant IM. Methotrexate vs cyclosporin in psoriasis: effectiveness, quality of life and safety. A randomized controlled trial. Br J Dermatol. 2008;158(1):116–21. https://doi.org/10.1111/j.1365-2133.2007.08284.x.PubMed

12.

Kragballe K, Jansen CT, Geiger JM, Bjerke JR, Falk ES, Gip L, et al. A double-blind comparison of acitretin and etretinate in the treatment of severe psoriasis. Results of a Nordic multicentre study. Actadermato-venereologica. 1989;69:35–40.

13.

Gollnick H, Bauer R, Brindley C, Orfanos CE, Plewig G, Wokalek H, et al. Acitretin versus etretinate in psoriasis. Clinical and pharmacokinetic results of a German multicenter study. J Am Acad Dermatol. 1988;19(3):458–68. https://doi.org/10.1016/S0190-9622(88)70198-X.CrossRefPubMed

14.

Berbis P, Geiger JM, Vaisse C, Rognin C, Privat Y. Benefit of progressively increasing doses during the initial treatment with acitretin in psoriasis. Dermatologica. 1989;178(2):88–92. https://doi.org/10.1159/000248398.CrossRefPubMed

15.

Menter A, Korman NJ, Elmets CA, Feldman SR, Gelfand JM, Gordon KB, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 4. Guidelines of care for the management and treatment of psoriasis with traditional systemic agents. J Am Acad Dermatol. 2009;61(3):451–85. https://doi.org/10.1016/j.jaad.2009.03.027.CrossRefPubMed

16.

• Papp K, Reich K, Leonardi CL, Kircik L, Chimenti S, Langley RG, et al. Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1). J Am Acad Dermatol. 2015;73:37–49. Pivotal study on apremilast and its use in psoriasis. CrossRefPubMed

17.

Paul C, Cather J, Gooderham M, Poulin Y, Mrowietz U, Ferrandiz C, et al. Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate-to-severe plaque psoriasis over 52 weeks: a phase III, randomized controlled trial (ESTEEM 2). Br J Dermatol. 2015;173(6):1387–99. https://doi.org/10.1111/bjd.14164.CrossRefPubMed

18.

•• Warren RB, Mrowietz U, von Kiedrowski R, Niesmann J, Wilsmann-Theis D, Ghoreschi K, et al. An intensified dosing schedule of subcutaneous methotrexate in patients with moderate to severe plaque-type psoriasis (METOP): a 52 week, multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017;389:528–37. This study provides a well designed evidence on the use of subcutaneous methotrexate in moderate to severe plaque psoriasis CrossRefPubMed

19.

Reich K, Langley RG, Papp KA, Ortonne JP, Unnebrink K, Kaul M, et al. A 52-week trial comparing briakinumab with methotrexate in patients with psoriasis. N Engl J Med. 2011;365(17):1586–96. https://doi.org/10.1056/NEJMoa1010858.CrossRefPubMed

20.

Carrascosa JM, de la Cueva P, Ara M, Puig L, Bordas X, Carretero G, et al. Methotrexate in moderate to severe psoriasis: review of the literature and expert recommendations. Actas dermo-sifiliograficas. 2016;107(3):194–206. https://doi.org/10.1016/j.ad.2015.10.005.CrossRefPubMed

21.

• Otero ME, van den Reek JM, Seyger MM, van de Kerkhof PC, Kievit W, de Jong EM. Determinants for drug survival of methotrexate in patients with psoriasis, split according to different reasons for discontinuation: results of the prospective MTX-CAPTURE. Br J Dermatol. 2017;177:497–504. Relevant real life data in patients using methotrexate. CrossRefPubMed

22.

West J, Ogston S, Palmer C, Fleming C, Dawe R, Kumar V, et al. Methotrexate in psoriasis under real-world conditions: long-term efficacy and tolerability. Br J Dermatol. 2016;174(6):1407–10. https://doi.org/10.1111/bjd.14452.CrossRefPubMed

23.

• Choi JH, Shin EJ, Shin MK, Kim NI. Immune parameters of Korean patients with psoriasis treated with low-dose cyclosporine. Ann Dermatol. 2017;29:111–3. This study provides a possible explanation about mechanism of action of low doses of cyclosporine. CrossRefPubMedPubMedCentral

24.

Colombo D, Banfi G, Cassano N, Graziottin A, Vena GA, Fiori GG, et al. The GENDER ATTENTION Observational Study: gender and hormonal status differences in the incidence of adverse events during cyclosporine treatment in psoriatic patients. Adv Ther. 2017;34(6):1349–63. https://doi.org/10.1007/s12325-017-0526-7.CrossRefPubMedPubMedCentral

25.

• Davila-Seijo P, Dauden E, Carretero G, Ferrandiz C, Vanaclocha F, Gomez-Garcia FJ, et al. Survival of classic and biological systemic drugs in psoriasis: results of the BIOBADADERM registry and critical analysis. J Eur Acad Dermatol Venereol: JEADV. 2016;30:1942–50. Extensive real life evidence of Spanish psoriatic population and their treatment. PubMed

26.

• Belinchon I, Ramos JM, Carretero G, Ferrandiz C, Rivera R, Dauden E, et al. Adverse events associated with discontinuation of the biologics/classic systemic treatments for moderate-to-severe plaque psoriasis: data from the Spanish Biologics Registry, Biobadaderm. J Eur Acad Dermatol Venereol : JEADV. 2017;31:1700–8. Another report of Spanish registry in psoriasis. CrossRefPubMed

27.

Lee MS, Chang CH, Lin RY, Lai MS. Risks of hypertension associated with cyclosporine, nonsteroidal anti-inflammatory drugs, and systemic glucocorticoids in patients with psoriasis: a nationwide population-based nested case-control study in Taiwan. Pharmacoepidemiol Drug Saf. 2016;25(2):133–40. https://doi.org/10.1002/pds.3890.CrossRefPubMed

28.

Balmer JE, Blomhoff R. Gene expression regulation by retinoic acid. J Lipid Res. 2002;43(11):1773–808. https://doi.org/10.1194/jlr.R100015-JLR200.CrossRefPubMed

29.

Bauer R, Schutz R, Orfanos CE. Impaired motility and random migration of vital polymorphonuclears in vitro after therapy with oral aromatic retinoid in psoriasis. Int J Dermatol. 1984;23(1):72–7. https://doi.org/10.1111/j.1365-4362.1984.tb05670.x.CrossRefPubMed

30.

Murray HE, Anhalt AW, Lessard R, Schacter RK, Ross JB, Stewart WD, et al. A 12-month treatment of severe psoriasis with acitretin: results of a Canadian open multicenter study. J Am Acad Dermatol. 1991;24(4):598–602. https://doi.org/10.1016/0190-9622(91)70091-F.CrossRefPubMed

31.

van de Kerkhof PC, Cambazard F, Hutchinson PE, Haneke E, Wong E, Souteyrand P, et al. The effect of addition of calcipotriol ointment (50 micrograms/g) to acitretin therapy in psoriasis. Br J Dermatol. 1998;138(1):84–9. https://doi.org/10.1046/j.1365-2133.1998.02030.x.CrossRefPubMed

32.

Dogra S, Yadav S. Acitretin in psoriasis: an evolving scenario. Int J Dermatol. 2014;53(5):525–38. https://doi.org/10.1111/ijd.12365.CrossRefPubMed

33.

Tanew A, Guggenbichler A, Honigsmann H, Geiger JM, Fritsch P. Photochemotherapy for severe psoriasis without or in combination with acitretin: a randomized, double-blind comparison study. J Am Acad Dermatol. 1991;25(4):682–4. https://doi.org/10.1016/0190-9622(91)70253-X.CrossRefPubMed

34.

Lowe NJ, Prystowsky JH, Bourget T, Edelstein J, Nychay S, Armstrong R. Acitretin plus UVB therapy for psoriasis. Comparisons with placebo plus UVB and acitretin alone. J Am Acad Dermatol. 1991;24(4):591–4. https://doi.org/10.1016/0190-9622(91)70089-K.CrossRefPubMed

35.

White SI, Marks JM, Shuster S. Etretinate in pustular psoriasis of palms and soles. Br J Dermatol. 1985;113(5):581–5. https://doi.org/10.1111/j.1365-2133.1985.tb02382.x.CrossRefPubMed

36.

Foged E, Holm P, Larsen PO, Laurberg G, Reymann F, Roesdahle K, et al. A randomized trial of etretinate (Tigason) in palmoplantar pustulosis. Dermatologica. 1983;166(4):220–3. https://doi.org/10.1159/000249872.CrossRefPubMed

37.

Ozawa A, Ohkido M, Haruki Y, Kobayashi H, Ohkawara A, Ohno Y, et al. Treatments of generalized pustular psoriasis: a multicenter study in Japan. J Dermatol. 1999;26(3):141–9. https://doi.org/10.1111/j.1346-8138.1999.tb03444.x.CrossRefPubMed

38.

Schafer P. Apremilast mechanism of action and application to psoriasis and psoriatic arthritis. Biochem Pharmacol. 2012;83(12):1583–90. https://doi.org/10.1016/j.bcp.2012.01.001.CrossRefPubMed

39.

Reich K SJ, Day R, et al. Change in weight with apremilast, an oral phosphodiesterase 4 inhibitor: pooled analysis of the ESTEEM 1 and ESTEEM 2 trials. Poster. Presented at: the 73rd Annual Meeting of the American Academy of Dermatology; 2015 Mar 20–24; San Francisco, CA.

40.

Dattola A, Del Duca E, Saraceno R, Gramiccia T, Bianchi L. Safety evaluation of apremilast for the treatment of psoriasis. Expert Opin Drug Saf. 2017;16(3):381–5. https://doi.org/10.1080/14740338.2017.1288714.CrossRefPubMed

41.

Chiricozzi A, Saraceno R, Novelli L, Fida M, Caso F, Scarpa R, et al. Small molecules and antibodies for the treatment of psoriasis: a patent review (2010-2015). Expert Opin Ther Patents. 2016;26(7):757–66. https://doi.org/10.1080/13543776.2016.1192129.CrossRef

42.

Xeljanz [package insert].New York, NY: Pfizer Laboratories; 2015.

43.

Fleischmann R, Kremer J, Cush J, Schulze-Koops H, Connell CA, Bradley JD, et al. Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis. N Engl J Med. 2012;367(6):495–507. https://doi.org/10.1056/NEJMoa1109071.CrossRefPubMed

44.

van Vollenhoven RF, Fleischmann R, Cohen S, Lee EB, Garcia Meijide JA, Wagner S, et al. Tofacitinib or adalimumab versus placebo in rheumatoid arthritis. N Engl J Med. 2012;367(6):508–19. https://doi.org/10.1056/NEJMoa1112072.CrossRefPubMed

45.

Papp KA, Menter A, Strober B, Langley RG, Buonanno M, Wolk R, et al. Efficacy and safety of tofacitinib, an oral Janus kinase inhibitor, in the treatment of psoriasis: a phase 2b randomized placebo-controlled dose-ranging study. Br J Dermatol. 2012;167(3):668–77. https://doi.org/10.1111/j.1365-2133.2012.11168.x.CrossRefPubMed

46.

• Bachelez H, van de Kerkhof PC, Strohal R, Kubanov A, Valenzuela F, Lee JH, et al. Tofacitinib versus etanercept or placebo in moderate-to-severe chronic plaque psoriasis: a phase 3 randomised non-inferiority trial. Lancet (London, England). 2015;386:552–61. First phase III study showing a non inferiority assessment of a small molecule compared to a biologic in psoriasis. CrossRef

47.

Valenzuela F, Bissonnette R, Bakos N, TsaiT-F, Harper MK, Ports WC, et al. Tofacitinib in patients with moderate to severe chronic plaque psoriasis: long-term efficacy and safety up to 54 months in an open-label extension study. In: Program and abstracts, 26th EADV Congress; 13–17 September 2017, Geneva, Switzerland.

48.

Langley R CA, Foley P, et al. Safety of tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: integrated data analysis from the global clinical trials. In: Program and abstracts, 73rd Annual Meeting of the American Academy of Dermatology; March 20, 2015; San Francisco, CA.

49.

US Food and Drug Administration. Arthritis Advisory Committee Meeting. NDA 203214: tofacitinib for the treatment of adult patients with moderately to severely active rheumatoid arthritis who have had inadequate response to one or more disease-modifying anti-rheumatic drugs. May 9, 2012.

50.

Pfizer receives complete response letter from FDA for oral XELJANZ® (tofacitinib citrate) supplemental new drug application for moderate to severe chronic plaque psoriasis [press release]. New York, NY: Pfizer Inc. October 14, 2015.

51.

Ports WC, Khan S, Lan S, Lamba M, Bolduc C, Bissonnette R, et al. A randomized phase 2a efficacy and safety trial of the topical Janus kinase inhibitor tofacitinib in the treatment of chronic plaque psoriasis. Br J Dermatol. 2013;169(1):137–45. https://doi.org/10.1111/bjd.12266.CrossRefPubMedPubMedCentral

52.

Concert pharmaceuticals Inc. Deuterated derivatives of ruxolitinib WO2013188783A1. 2013.

53.

Punwani N, Scherle P, Flores R, Shi J, Liang J, Yeleswaram S, et al. Preliminary clinical activity of a topical JAK1/2 inhibitor in the treatment of psoriasis. J Am Acad Dermatol. 2012;67(4):658–64. https://doi.org/10.1016/j.jaad.2011.12.018.CrossRefPubMed

54.

Ortiz-Ibanez K, Alsina MM, Munoz-Santos C. Tofacitinib and other kinase inhibitors in the treatment of psoriasis. Actas dermo-sifiliograficas. 2013;104(4):304–10. https://doi.org/10.1016/j.adengl.2013.03.002.CrossRefPubMed

55.

Papp KA, Menter MA, Raman M, Disch D, Schlichting DE, Gaich C, et al. A randomized phase 2b trial of baricitinib, an oral Janus kinase (JAK) 1/JAK2 inhibitor, in patients with moderate-to-severe psoriasis. Br J Dermatol. 2016;174(6):1266–76. https://doi.org/10.1111/bjd.14403.CrossRefPubMed

56.

Hansen RB, Kavanaugh A. Novel treatments with small molecules in psoriatic arthritis. Curr Rheumatol Rep. 2014;16(9):443. https://doi.org/10.1007/s11926-014-0443-6.CrossRefPubMed

57.

Papp K, Pariser D, Catlin M, Wierz G, Ball G, Akinlade B, et al. A phase 2a randomized, double-blind, placebo-controlled, sequential dose-escalation study to evaluate the efficacy and safety of ASP015K, a novel Janus kinase inhibitor, in patients with moderate-to-severe psoriasis. Br J Dermatol. 2015;173(3):767–76. https://doi.org/10.1111/bjd.13745.CrossRefPubMed

58.

Can-Fite Biopharma Ltd. Pharmaceutical composition comprising a3 adenosine receptor agonist (ib-meca/cf-101) for treatment of psoriasis. WO2011027348A1. 2011.

59.

Fishman P, Bar-Yehuda S, Liang BT, Jacobson KA. Pharmacological and therapeutic effects of A3 adenosine receptor agonists. Drug Discov Today. 2012;17(7-8):359–66. https://doi.org/10.1016/j.drudis.2011.10.007.CrossRefPubMed

60.

David M, Akerman L, Ziv M, Kadurina M, Gospodinov D, Pavlotsky F, et al. Treatment of plaque-type psoriasis with oral CF101: data from an exploratory randomized phase 2 clinical trial. J Eur Acad Dermatol Venereol : JEADV. 2012;26(3):361–7. https://doi.org/10.1111/j.1468-3083.2011.04078.x.CrossRefPubMed

Title: Update on Oral Therapy for Psoriasis
Authors: Fernando Valenzuela
Javier Fernández
Pablo Santa María
Publication date: 01-03-2018
Publisher: Springer US
Published in: Current Dermatology Reports / Issue 1/2018
Electronic ISSN: 2162-4933
DOI: https://doi.org/10.1007/s13671-018-0212-2

At a glance: The STEP trials

Springer Medicine

Update on Oral Therapy for Psoriasis

Abstract

Purpose of Review

Recent Findings

Summary

At a glance: The STEP trials

Springer Medicine

Abstract

Purpose of Review

Recent Findings

Summary

Please log in to get access to this content

Other articles of this Issue 1/2018

Update on Noninvasive Diagnostic Imaging and Management of Nonmelanoma Skin Cancer

A Review and Update of Phototherapy Treatment Options for Psoriasis

Enteropathy in Psoriasis: A Systematic Review of Gastrointestinal Disease Epidemiology and Subclinical Inflammatory and Functional Gut Alterations

Effects of Biologic Therapy on Cardiovascular Disease in Psoriasis

Review Update on Topical Therapy for Psoriasis

Evaluation of the Itchy Patient